[go: up one dir, main page]

WO2008021681A2 - Système et procédés permettant d'analyser des images d'échantillons tissulaires - Google Patents

Système et procédés permettant d'analyser des images d'échantillons tissulaires Download PDF

Info

Publication number
WO2008021681A2
WO2008021681A2 PCT/US2007/074388 US2007074388W WO2008021681A2 WO 2008021681 A2 WO2008021681 A2 WO 2008021681A2 US 2007074388 W US2007074388 W US 2007074388W WO 2008021681 A2 WO2008021681 A2 WO 2008021681A2
Authority
WO
WIPO (PCT)
Prior art keywords
region
images
subcellular
cytoplasm
rtks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/074388
Other languages
English (en)
Other versions
WO2008021681A3 (fr
Inventor
Robert John Filkins
Harvey Ellis Cline
Michael Christopher Montalto
Sudeshna Adak
Ali Can
Michael J. Gerdes
Melinda Larsen
Fiona Ginty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Electric Co
Original Assignee
General Electric Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/500,028 external-priority patent/US8131476B2/en
Priority claimed from US11/606,582 external-priority patent/US8060348B2/en
Priority claimed from US11/686,649 external-priority patent/US20080032321A1/en
Application filed by General Electric Co filed Critical General Electric Co
Priority to EP07813372A priority Critical patent/EP2049678A2/fr
Publication of WO2008021681A2 publication Critical patent/WO2008021681A2/fr
Anticipated expiration legal-status Critical
Publication of WO2008021681A3 publication Critical patent/WO2008021681A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/0002—Inspection of images, e.g. flaw detection
    • G06T7/0012—Biomedical image inspection

Definitions

  • the invention relates generally to tissue processing, image analysis, and disease prognosis.
  • Immunohistochemisty using peroxidase enzyme amplification and diaminobenzidine (DAB) substrate is the standard technique used to assess the spatial location and qualitative expression patterns of proteins in tumor and other tissue samples.
  • this technique is inadequate to finely assess the quantity of proteins in a tissue sample.
  • This limitation is due, in part, to the low dynamic range of bright field microscopy, which is further exacerbated by the inherent enzymatic amplification of peroxidase-based immunostaining.
  • current quantification requires the subjective interpretation of low (1+), medium (2+) and high (3+) intensity.
  • receptor tyrosine kinases possess an extracellular ligand binding domain, a transmembrane domain and an intracellular catalytic domain.
  • the transmembrane domain anchors the receptor in the plasma membrane, while the extracellular domains bind growth factors.
  • the intracellular kinase domains of RTKs can be divided into two classes: those containing a stretch of amino acids separating the kinase domain and those in which the kinase domain is continuous. Activation of the kinase is achieved by ligand binding to the extracellular domain, which induces dimerization of the receptors.
  • Receptors thus activated are able to autophosphorylate tyrosine residues outside the catalytic domain via cross- phosphorylation.
  • the results of this auto-phosphorylation are stabilization of the active receptor conformation and the creation of phosphotyrosine docking sites for proteins that transduce signals within the cell.
  • Translocation activities are used in the embodiments of the methods described as indicators of cancers, including but not limited to colon cancer and other epithelial-based cancers and inflammatory diseases.
  • the methods provide simultaneous, accurate measurement of membrane, cytoplasm, and/or nuclear levels of cMet RTK, which is used as a biomarker in one or more of the embodiments described for colon cancer. These methods also provide a superior approach to traditional IHC and new insights into cell activation status and disease pathology.
  • the methods and systems of the invention create an automated image analysis framework that can be used automatically quantify and score digital images of tissue samples for a variety of applications including, but not limited to, screening patients for cancer, and even specific stages and types of cancer, and other diseases and to identify and quantify multiple biomarkers in a single tissue sections to develop cancer drug therapies, toxicology evaluation and research.
  • the technical effect of these methods and systems is to enable automatic analysis of multi-channel tissue images; simultaneous analysis/quantification of multiple biomarkers; high throughput analysis of large patient cohorts; spatially resolved quantification; and compartment based biomarker analysis for cancer scoring. Multiple biomarkers that express different pathways may be used in prescribing therapy.
  • the methods and systems of the invention generally directed at digital microscopy are adapted to replace visual observation and image processing as an important aid to pathologists and researchers.
  • TMAs comprising tissue from colon cancer patients and applies fluorescent based immunohistochemistry to identify the cell membrane (using pan- cadherin antibody), cMet (extracellular domain), and cell nuclei (using DAPI).
  • a mask of the stromal region is generated, and using curvature and geometry based segmentation, the membrane and nuclear regions of the tumor region are demarcated.
  • the cytoplasm is generally defined as the area between the membrane and nucleus or within the membrane space. Probability distributions of cMet within the membrane, nuclei or cytoplasm are determined, and an automated scoring algorithm that assigns cMet scores for each compartment is generated. Thresholds associated with a significant difference in survival time can also be determined using these systems and methods.
  • An example embodiment of the system for analyzing tissue samples generally comprises: a storage device for at least temporarily storing one or more images of one or more cells, wherein at least one of the images is indicative of one or more channels comprising a receptor tyrosine kinase (RTK); and a processing device that determines an extent to which one or more of the RTKs may have translocated from at least one subcellular region to another subcellular region of one or more of the cells; and generates a score based at least in part on the RTK translocation, wherein at least one of the RTKs may be cMet.
  • One or more of the subcellular regions may be at least a portion of a membrane, cytoplasm or nucleus.
  • the score may be used for a variety of purposes including, but not limited to, determining the location of the RTKs and their activation status in cancer and non-cancer tissues.
  • the score and location information may be used indicate whether the tissue comprises cancerous tissue such as, but not limited to, epithelial cancers such as, but again not limited to, breast cancer, colon cancer and melanoma.
  • the scores and information may also be used to predict response to RTK-related therapies and research applications such as, but not limited to, drug discovery and cellular mechanisms of disease
  • the images may reflect channels that are enhanced using one or more morphological stains and/or one or more biomarkers.
  • the subcellular regions may comprise, but are limited to, the membrane, the cytoplasm, the stroma, epithelial nuclei, and stromal nuclei.
  • the processor determines the extent to which one or more of the RTKs has translocated at least in part by segmenting at least one of the images into one or more subcellular regions, and determining one or more metrics of translocation of at least one of the RTKs in a membrane region and in a cytoplasm region.
  • the processor may be configured to segment the images at least in part based on a probability map of a plurality of pixels making up the images; wherein the probability map reflects the likelihood that one or more of the pixels belongs to one or more of the subcellular regions.
  • the subcellular regions may comprise, but are limited to, the membrane, the cytoplasm, the stroma, epithelial nuclei, and stromal nuclei.
  • the steps generally comprise: providing one or more images of one or more cells, wherein at least one of the images is indicative of one or more channels comprising a receptor tyrosine kinase (RTK); and determining an extent to which one or more of the RTKs may have translocated from at least one subcellular region to another subcellular region of one or more of the cells.
  • the method may also generate a score based at least in part on the RTK translocation, wherein the score may indicate activation status, disease status and prognosis.
  • the RTK may be, but is not necessarily limited to, cMet, and the subcellular regions may comprise, but are not limited to, the membrane, the cytoplasm, the stroma, epithelial nuclei, and stromal nuclei.
  • One of the example methods may determine the extent of translocation in part by segmenting at least one of the images into one or more subcellular regions; and may further comprise the step of determining a metric of translocation of at least one of the RTKs in a membrane region and in a cytoplasm region.
  • the step of segmenting may, at least in part, use a probability map of a plurality of pixels making up the images, wherein the probability map reflects the likelihood that one or more of the pixels belongs to one or more of the subcellular regions.
  • FIG. 1 shows data and results for DAPI and IGg normalized cMet knockdown vs control cells used in one of the example embodiments of the systems and methods of the invention.
  • FIG. 2 A shows the measured intensities of an embodiment of a multiple channel image using a plurality of markers showing the nuclei as stained with DAPI, the membrane as stained with pan-cadherin, and the target protein cMet.
  • FIG. 2B shows a probability map for the subcellar nuclear regions shown in FIG. 2A.
  • FIG. 2C shows a probability map for the subcellular membrane regions shown in FIG. 2A.
  • FIG. 2D shows a probability map for the several subcellular regions, the membrane, epithelial nuclei, stromal nuclei, and cytoplasm.
  • FIG. 2E shows the probability distribution function for one of the embodiments that, in this example uses cMet as the target protein, is used to determine the weighted distribution of the target protein.
  • FIG. 3 shows the distribution of a score overall and by the stages of a disease, as used in one of the embodiments that uses an MCT score and reflects a disease that exhibits a plurality of stages.
  • FIG. 4 shows four graphs of survival curves for all patients from an example of an embodiment described, the first of which reflects all three stages and the other three of which reflect stage 1- 3 patients subdivided into high and low risk groups based on MCT score thresholds.
  • FIG. 5 is a schematic diagram of an embodiment of the automated system for carrying out the methods.
  • CMet also known as Met, hepatocyte growth factor or scatter factor receptor.
  • CMet is a heterodimer with an extracellular domain (the alpha subunit), and a beta subunit, which is comprised of a transmembrane domain, juxtamembrane and kinase domain.
  • the juxtamembrane domain has an inhibitory function for cMet activation, where phosphorylation of the serine residue (S985) or tyrosine residue (Y 1003) results in ubiquitinization, endocytosis and degradation of cMet.
  • the C-terminal tail contains a docking site responsible for recruitment of downstream signaling molecules.
  • the tissue used in the methods and systems is fixed or otherwise provided on a substrate such as, but not limited to, a TMA, a slide, a well, or a grid.
  • the tissue is labeled with molecular biomarkers, and imaged through a fluorescent microscope. Then the tissue is re-labeled with one or more morphological stains and imaged again.
  • the methods are not limited to a particular sequence of applying one or more stains, nor are the methods limited to two images and can be adapted to co-register more than two images as needed.
  • the images are overlaid using both hardware and software registration techniques, and the information is merged, whereby one of the technical effects is to co-register or otherwise produce multi-channel images.
  • Fluorescent-based immunohistochemistry is used in some of the example embodiments to identify cellular regions such as the cell membrane, cytoplasm and nuclei.
  • cellular regions such as the cell membrane, cytoplasm and nuclei.
  • a mask of the stromal region is generated, and using curvature and geometry based segmentation, the membrane and nuclear regions of a given tumor region are demarcated.
  • the cytoplasm is designated as the area between the membrane and nucleus or within the membrane space.
  • the probability distribution of cMet within the membrane, nuclei or cytoplasm is determined, and a cMet score is generated, for each compartment. Thresholds associated with a significant difference in survival time may also be determined.
  • morphological markers Any number and type of morphological markers may be used in the methods including, but not limited to, the following:
  • Keratin marker for epithelial cells
  • Pan-cadherin marker for the cell membrane
  • DAPI marker for the nucleus
  • Eosin marker for cytoplasm depends on pH (red stain).
  • Some of these morphological markers can be imaged using a bright field microscope, and some with a fluorescent microscope.
  • the methods and systems of the invention may be used to personalized therapy and enhance disease research and cancer drug development.
  • One example of the systems and methods uses pan-cadherin as a morphological stain for the cell membrane and cMet receptor tyrosine kinase as the biomarker.
  • tissue microarrays were constructed with histospots (0.6mm in diameter) spaced 0.8mm apart in a grid layout using a manual Tissue Microarrayer (Beecher Instruments, Silver Spring, MD).
  • the resulting tissue microarray blocks were cut to 5 ⁇ m sections with a microtome, the sections were placed on slides with an adhesive tape-transfer method (Instrumedics, Inc., Hackensack, NJ), and were UV cross-linked for subsequent use in antibody optimization protocols.
  • a commercial antibody directed against the extracellular domain of cMet (clone DO-24, Upstate Biotechnology, Lake Placid, NY) was optimized in this example for fluorescent immunohistochemistry in human tissue using formalin-fixed paraffin-embedded tissues (including colon, breast, stomach, prostate, kidney, muscle, liver, brain, skin and lymph) from the archives of the Yale University. Series of serial dilutions were evaluated on test tissue arrays, each containing 10-20 histospots, to identify the optimal concentration of DO-24 that provided a wide dynamic range of staining.
  • a breast cancer cell line array called "MaxArray” (Zymed, San Francisco, cat# 75-3023) was used as a positive control for cMet staining and a "no primary" negative control slide was included. Cytoplasmic and membranous staining of cMet was observed in all tissue types and a DO-24 dilution of 1 :2000 was determined to be optimal. Secondary antibody and TSA amplification detection used.
  • METHSS 106479 was found to give optimal knockdown, as determined by Western analysis using an anti-CMet antibody (C- 12, Santa Cruz Biotechnology, Santa Cruz, CA, Cat. Sc-10) to detect protein levels in RIPA buffer cell extracts.
  • the final concentration of siRNA in the media was 25pMol.
  • Cells were fixed following 48 hr culture with 4% PFA and embedded in paraffin, as previously described (Dolled-Filhart, McCabe et al. 2006). Five micron sections from each paraffin block were immunostained with DO-24 antibody at 1 :2000, as described for the IHC of TMAs, except that the second blocking step used 10% donkey serum.
  • Pan- cadherin was detected using anti-pan-cadherin at 1 : 100, 37C, 1 hr (Lab Vision, Cat. RB9036)) with Cy3 -conjugated AffiniPure F(ab) 2 fragment Donkey anti-rabbit IgG (Jackson ImmunoResearch, Cat.
  • TMAs were deparaffinized first by heating at 6O 0 C, then by two xylene rinses followed by two rinses with 100% ethanol and a rinse in water.
  • Antigen retrieval was performed in a Tris-EDTA buffer at a pH of 9.0 in the PT Module device (Lab Vision). After rinsing briefly in IX Tris-buffered saline (TBS), a 30- minute incubation with 2.5% hydrogen peroxide/methanol block was used to block endogenous peroxidases, followed by incubation with 10% goat serum (Gibco, cat# 16210-064) for one hour at room temperature.
  • the anti-cMet antibody DO-24 was incubated overnight at 4 0 C at a dilution of 1 :2000.
  • the anti-cMet antibody was detected with Envision anti-mouse labeled polymer HRP (DAKO, product # K4001), followed by Cy5 tyramide (1 :50, Perkin Elmer, product #SAT705A). All slides were then incubated overnight at 4 0 C in a cocktail of a rabbit anti-pan-cadherin antibody (Abeam, 1 : 1000, product #Ab6529-200) for membrane identification and a monoclonal mouse anti-cytokeratin antibody (clone AE1/AE3, DAKO, 1 :200, product #M3515).
  • Pan-cadherin was detected by incubation with biotin goat anti-rabbit (Jackson ImmunoResearch, product #111-065-144, 1 :200) for 60 minutes, followed by Cy-2 conjugated streptavidin (Jackson ImmunoResearch, product #016-220-084, 1 :200) for 30 minutes. Slides were mounted using Prolong Gold Anti fade w/DAPI mounting gel (Invitrogen/Molecular Probes, product #P36931). Images were captured using a PM-2000TM microscopy platform (HistoRx, New Haven, CT) at 2OX magnification with an exposure time for the Cy5 channel of 400ms.
  • the multiple channel digital images are partitioned into multiple regions (segments/compartments) to quantify one or more biomarkers, such as cMet.
  • the quantification can be accomplished without determining definite decisions for each pixel, but rather by computing the likelihood that a given pixel belongs to a cellular region. For example, instead of identifying membrane pixels, the likelihood of a pixel being a membrane can be computed, which is essentially the probability of a pixel being a membrane. Probability maps of these pixel regions are computed using the intensity and geometry information provided by each channel. The preferred methods for created these probability maps are disclosed in U.S. Application Serial No.
  • FIG. 2A shows the measured intensities of a multiple channel image using a plurality of markers showing the nuclei as stained with DAPI, the membrane as stained with pan-cadherin, and the target protein cMet.
  • the probability maps computed for the nuclei and membrane are shown in Figure 2B and 2C, respectively.
  • the brightness of these images represents the probability value; white representing the probability value of one, black representing the probability value of zero, and any shade of gray being proportional with the probability value.
  • a definite decision for each pixel may be determined by thresholding the probability maps.
  • Such decisions are used in one or more of the embodiments to separate the epithelial nuclei from the stromal nuclei, and to detect the cytoplasm.
  • the cytoplasm is also represented as a probability map of ones and zeros.
  • Figure 2D shows the computed different regions; membrane, epithelial nuclei, stromal nuclei, and cytoplasm. Regions are excluded in this embodiment of the quantification step. Both the background and the extra cellular matrix are shown as black.
  • Translocation of a target protein between different regions is quantified in one or more of the embodiments using probability mapping.
  • the distribution of cMet in each of the regions was represented by a probability distribution function (PDF).
  • PDF probability distribution function
  • FIG. 2E shows the PDF of the target cMet on each of the regions.
  • the PDF of cMet on the membrane is the weighted empirical distribution of the cMet, where the membrane probability map determines the weights.
  • the mean and the standard deviation of cMet distribution are denoted in this example on each of the regions as ⁇ R , and ⁇ R , respectively, where R can be any of the nuclei, membrane, cytoplasm or non-epithelial extra cellular matrix (ECM) regions.
  • ECM extra cellular matrix
  • ECM in this example is defined as all the non-background pixels not classified as nuclei, membrane or cytoplasm.
  • the translocation score is the normalized mean difference between the cMet distributions on different regions.
  • MCT membrane to cytoplasm translocation
  • ⁇ R 2 ⁇ (c - ⁇ R ) 2 f c R (c) . ( 6 )
  • translocation score is defined in this embodiment as the normalized mean difference between the corresponding PDFs. All translocation scores are then related with clinical outcome, and tested for statistical significance to explore the association with the life expectancy.
  • a robust and cross-validated method is used in this embodiment to define an optimal threshold for each score that separates the patients into two groups having a maximum difference in survival.
  • the two groups defined by the threshold are then considered relative to each other as the low risk and high risk groups.
  • a threshold may be used to minimize the log rank test p-value between the two groups, with adjustments for multiple testing as the threshold is determined by repeated testing at each possible cut point.
  • the following cross-validated steps may be used: a. 2-fold Cross-validation: The data is divided into training and test data sets, with 50% of the cases (both censored and uncensored) being selected as training and the remaining as test; b.
  • Threshold Selection For each training data set, an optimal threshold is selected by the minimizing the log rank test p-value and an adjusted p-value (for multiple testing) is also computed; c. Cross-validation of Threshold: The optimal threshold is applied to the corresponding test data set and the log rank p-value for comparing the two groups is computed; d. Computing a robust threshold: The above three steps are repeated 500 times and the median of thresholds, hazard ratios and p-values from the 500 cross- validation runs is used. The final robust threshold is this median threshold.
  • Test of association between risk category and clinical/pathological stage variables are performed using chi-square test of association in a contingency table.
  • a Kaplan-Meier method may be used to estimate the median survival and survival rates in each risk group and Cox regression used to assess the prognostic value of the risk category in a multivariate analysis.
  • a stepwise selection procedure SAS v9.0 is used to select the variables that are independent prognostic factors.
  • the membrane cytoplasm translocation score (MCT score) is the preferred predictor of survival (training and test-set p-values in the cross-validation study ⁇ 0.1).
  • FIG. 4A shows the survival curves for all patients, while FIGS. 4B-D show the same survival curves for stages 1-3 patients, respectively, subdivided into high and low risk groups based on the MCT score thresholds.
  • thresholds were identified that significantly differentiated patients (all, stage I and stage II) into higher risk and lower risk groups. For example, higher risk patients with a shorter survival time had low MCT scores and lower risk patients with a longer survival time had high MCT scores. In this example, for all patients combined, the threshold MCT score was identified as -0.07, which means that a score of -0.07 and lower indicated a poor prognosis overall. For stage I patients, the threshold was 0.12 and for stage III patients, the threshold was -0.07.
  • the results of the 500 cross-validation runs are summarized in Table 1 for deaths due to the disease as the endpoint, showing the median split points, hazard ratios and p-values from the 500 cross-validation runs.
  • Table 1 the membrane score and the cytoplasm score reflect subtraction of the ECM from the membrane and subtraction of the ECM from the cytoplasm, respectively.
  • Table 1 Results of two-fold cross-validation of threshold selection on the membrane, cytoplasm and membrane cytoplasm translocation scores with death due to disease as the endpoint.
  • the MCT score also has a test set log rank p-value of 0.07 in stage I and stage II patients.
  • the median of the optimal split points is -0.07 in all patients, 0.12 in stage I patients and -0.07 in stage II patients.
  • the percentages of cases that fell into the high-risk category are: 14% in Stage I, 14% in Stage II, 17% in Stage III, and 22% in Stage IV.
  • the clinical and pathological data are then correlated with the expression of cMet.
  • the associative correlations between clinical and pathological variables such as but not limited to, age, stage of disease at diagnosis, pathological stage, histology and histology grade, and MCT score group are summarized in Table 2.
  • the other significant predictors of survival from death due to disease are age, stage of diagnosis, N Stage, T Stage and overall TNM Stage, as shown in Table 4.
  • stage at diagnosis p ⁇ 0.0001 is the only other significant predictor of survival from death due to disease in univariate Cox regression, though age was also a significant predictor when overall survival is considered.
  • Variables considered significant in univariate analyses are included in this example of multivariate analyses and stepwise selection is used to select those that are significant predictors of survival in multivariate analysis.
  • the results of the multivariate Cox regression with stepwise selection are shown in Table 4.
  • the MCT score is selected as a significant predictor even with stepwise selection indicating its significance as an independent prognostic factor for both survival and survival from death due to disease.
  • Stage, TNM stage, MCT score and age are to significant to varying degrees.
  • the methods and systems comprise automated scoring methods that employ curvature-based segmentation and assign probability distributions of a biomarker within a given area.
  • cMet cytoplasm to membrane distribution is used a predictor of outcome in: overall population; and in a more specific embodiment in stage I and II colon cancer patients.
  • One or more of the embodiments of the methods and systems effectively generates a score for cancer patients, and in more specific embodiments generates a score for colon cancer, referred to a membrane to cytoplasm translocation score (MCT score), that is a significant predictor of disease related survival and, in more specific embodiments, a predictor of overall survival in stage I and II patients.
  • MCT score membrane to cytoplasm translocation score
  • the automated system 10 for carrying out the methods generally comprises: a storage device 12 for at least temporarily storing one or more images of one or more cells, wherein the images comprise a plurality of channels; and a processor 14 comprising, a means for determining an extent to which a biomarker may have translocated from at least one subcellular region to another subcellular region; and a means for generating a score corresponding to the extent of translocation.
  • the score may indicate whether the patient's prognosis is poor and whether the tissue is cancerous and/or is metastasizing.
  • the system may be adapted to determine scores directed at translocation that indicates the presence of cancer.
  • the system may be further adapted to determine translocation indicative of a specific group of cancers such as epithelial cancer and more specifically colon cancer. However, the system is not necessarily limited to epithelial cancers or to colon cancer.
  • the means for determining the extent of the translocation may comprise one or more processing mechanisms such as one or more algorithms residing in a memory device associated with the processor or a sub processor, or an external processor that is capable of communicating with the processor.
  • the mean for determining the extent to which the biomarker has translocated may determine the translocation at least in part using one or more appropriate segmentation steps of the methods.
  • the system may segment at least one image comprising a biomarker channel and at least one image comprising a morphological channel into subcellular regions, and a metric of translocation of the biomarker in a membrane subcellular region and another subcellular region.
  • the storage device may comprise, but is not necessarily limited to, any suitable hard drive memory associated with the processor such as the ROM (read only memory), RAM (random access memory) or DRAM (dynamic random access memory) of a CPU (central processing unit), or any suitable disk drive memory device such as a DVD or CD, or a zip drive or memory card.
  • the storage device may be remotely located from the processor or the means for displaying the images, and yet still be accessed through any suitable connection device or communications network including but not limited to local area networks, cable networks, satellite networks, and the Internet, regardless whether hard wired or wireless.
  • the processor or CPU may comprise a microprocessor, microcontroller and a digital signal processor (DSP).
  • DSP digital signal processor
  • the storage device 12 and processor 14 may be incorporated as components of an analytical device such as an automated high-throughput system that stains and images the TMAs in one system and still further analyzes the images the generate a score.
  • an analytical device such as an automated high-throughput system that stains and images the TMAs in one system and still further analyzes the images the generate a score.
  • System 10 may further comprise a means for displaying 16 one or more of the images; an interactive viewer 18; a virtual microscope 20; and/or a means for transmitting 22 one or more of the images or any related data or analytical information over a communications network 24 to one or more remote locations 26.
  • the means for displaying 16 may comprise any suitable device capable of displaying a digital image such as, but not limited to, devices that incorporate an LCD or CRT.
  • the means for transmitting 22 may comprise any suitable means for transmitting digital information over a communications network including but not limited to hardwired or wireless digital communications systems.
  • the system may further comprise an automated device 28 for applying one or more of the stains and a digital imaging device 30 such as, but not limited to, an imaging microscope comprising an excitation source 32 and capable of capturing digital images of the TMAs.
  • a digital imaging device 30 such as, but not limited to, an imaging microscope comprising an excitation source 32 and capable of capturing digital images of the TMAs.
  • imaging devices are preferably capable of auto focusing and then maintaining and tracking the focus feature as needed throughout processing.
  • These multi-channel methods are not limited to morphological stains or fluorescent biomarkers or even to pathology. Any stain that enables some informative aspect or feature of a biological sample to be visualized so that it can be digitally imaged and processed would be suitable for these methods. Suitable stains include, but are not necessarily limited to, cytological or morphological stains, immunological stains such as immunohisto- and immunocyto- chemistry stains, cytogenetical stains, in situ hybridization stains, cytochemical stains, DNA and chromosome markers, and substrate binding assay stains. Other medical and bioscience applications can benefit from the extended multi-channels. These multichannel methods provide a flexible framework in which markers can be imaged sequentially without being limited to optical, chemical, and biological interactions. [0058] As noted, the methods and systems are suitable for any number of applications including, but not limited to, detecting and analyzing epithelial cancers such as, but not limited to, breast, colon and prostate cancers and melanoma.

Landscapes

  • Engineering & Computer Science (AREA)
  • Quality & Reliability (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Health & Medical Sciences (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un système, permettant d'analyser des échantillons de tissu, qui comprend : un dispositif de stockage destiné à stocker au moins temporairement une ou plusieurs images d'une ou de plusieurs cellules, l'une au moins des images étant représentative d'un ou de plusieurs canaux possédant un récepteur à activité tyrosine kinase (RTK) ; et un dispositif de traitement qui détermine l'ampleur de la translocation d'un ou de plusieurs RTK d'une zone subcellulaire au moins à une autre zone subcellulaire d'une ou de plusieurs cellules. Le système génère aussi une note reposant au moins partiellement sur la translocation du RTK.
PCT/US2007/074388 2006-08-07 2007-07-26 Système et procédés permettant d'analyser des images d'échantillons tissulaires Ceased WO2008021681A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07813372A EP2049678A2 (fr) 2006-08-07 2007-07-26 Système et procédés permettant d'analyser des images d'échantillons tissulaires

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US11/500,028 2006-08-07
US11/500,028 US8131476B2 (en) 2006-08-07 2006-08-07 System and method for co-registering multi-channel images of a tissue micro array
US11/606,582 2006-11-30
US11/606,582 US8060348B2 (en) 2006-08-07 2006-11-30 Systems for analyzing tissue samples
US11/680,063 US8036462B2 (en) 2006-08-07 2007-02-28 Automated segmentation of image structures
US11/680,063 2007-02-28
US11/686,649 2007-03-15
US11/686,649 US20080032321A1 (en) 2006-08-07 2007-03-15 System and methods for analyzing images of tissue samples

Publications (2)

Publication Number Publication Date
WO2008021681A2 true WO2008021681A2 (fr) 2008-02-21
WO2008021681A3 WO2008021681A3 (fr) 2009-03-19

Family

ID=39030806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/074388 Ceased WO2008021681A2 (fr) 2006-08-07 2007-07-26 Système et procédés permettant d'analyser des images d'échantillons tissulaires

Country Status (1)

Country Link
WO (1) WO2008021681A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8269827B2 (en) 2009-09-29 2012-09-18 General Electric Company System and methods for mapping fluorescent images into a bright field color space
WO2013167139A1 (fr) * 2012-05-11 2013-11-14 Dako Denmark A/S Procédé et appareil de comptage et d'analyse d'images
US8639013B2 (en) 2011-08-17 2014-01-28 General Electric Company System and methods for generating a brightfield image using fluorescent images

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAMP R L ET AL: "Automated subcellular localization and quantification of protein expression in tissue microarrays" NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 8, no. 11, 1 November 2002 (2002-11-01), pages 1323-1327, XP002406339 ISSN: 1078-8956 *
RESNICK MURRAY B ET AL: "Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study." CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 MAY 2004, vol. 10, no. 9, 1 May 2004 (2004-05-01), pages 3069-3075, XP002511853 ISSN: 1078-0432 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8269827B2 (en) 2009-09-29 2012-09-18 General Electric Company System and methods for mapping fluorescent images into a bright field color space
US8639013B2 (en) 2011-08-17 2014-01-28 General Electric Company System and methods for generating a brightfield image using fluorescent images
WO2013167139A1 (fr) * 2012-05-11 2013-11-14 Dako Denmark A/S Procédé et appareil de comptage et d'analyse d'images

Also Published As

Publication number Publication date
WO2008021681A3 (fr) 2009-03-19

Similar Documents

Publication Publication Date Title
EP2049678A2 (fr) Système et procédés permettant d'analyser des images d'échantillons tissulaires
US20080032321A1 (en) System and methods for analyzing images of tissue samples
JP5048757B2 (ja) 診断指標または予測指標としての細胞内局在プロフィールの使用
Bankhead et al. Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer
Brennan et al. Antibody-based proteomics: fast-tracking molecular diagnostics in oncology
Roepman et al. Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer
Symes et al. Quantitative analysis of BTF3, HINT1, NDRG1 and ODC1 protein over-expression in human prostate cancer tissue
JP5184087B2 (ja) ガンの予後のためのマーカー候補を分析および最適化するための方法およびコンピュータープログラム製品
Lee et al. Clinicopathologic significance of the intratumoral heterogeneity of HER2 gene amplification in HER2-positive breast cancer patients treated with adjuvant trastuzumab
Feuchtinger et al. Image analysis of immunohistochemistry is superior to visual scoring as shown for patient outcome of esophageal adenocarcinoma
Torrisi et al. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17
Rizzardi et al. Quantitative comparison and reproducibility of pathologist scoring and digital image analysis of estrogen receptor β2 immunohistochemistry in prostate cancer
Buglioni et al. Quantitative molecular analysis of sentinel lymph node may be predictive of axillary node status in breast cancer classified by molecular subtypes
Peck et al. Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms
Huvila et al. Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma
Robbins et al. HER2 testing: evolution and update for a companion diagnostic assay
Chao et al. Assessment of HER2 status using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) techniques in mucinous epithelial ovarian cancer: a comprehensive comparison between ToGA biopsy method and ToGA surgical specimen method
Hamada et al. Podoplanin is an efficient predictor of neck lymph node metastasis in tongue squamous cell carcinoma with low tumor budding grade
JP6417602B2 (ja) 大腸直腸癌の予後を判定する方法
Gatalica et al. Alpha-methylacyl-CoA racemase (AMACR) protein is upregulated in early proliferative lesions of the breast irrespective of apocrine differentiation
Theodosiou et al. Evaluation of FISH image analysis system on assessing HER2 amplification in breast carcinoma cases
McLemore et al. HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines
WO2008021681A2 (fr) Système et procédés permettant d'analyser des images d'échantillons tissulaires
Nassar et al. Trainable immunohistochemical HER2/neu image analysis: a multisite performance study using 260 breast tissue specimens
Guerriero et al. Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007813372

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: RU